Shiv Texchem (544272)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Profit growth of 108.19% and sales growth of 45.83% show strong recent momentum.
• P/E of 3.80 and PEG of 0.05 indicate deeply undervalued earnings relative to growth.
• Piotroski F-Score of 7/9 suggests solid financial health and improving fundamentals.
• ROCE of 14.46% is reasonable for a low-margin chemical trading business.
• Latest quarter net profit of ₹43 Cr on ₹1,503 Cr sales demonstrates meaningful operating scale.

Concerns

• Chemical trading lacks a durable competitive moat and operates on thin margins (~2.9%).
• Zero dividend yield means returns depend entirely on price appreciation and reinvestment.
• Key data missing: promoter holding, book value, and debt-to-equity ratio reduce analytical confidence.
• High profit growth may be cyclical and not sustainable in a volatile chemical trading market.

AI Analysis

At first glance, Shiv Texchem has the numbers value investors dream about: a P/E of 3.80, sales growth of 45.83%, and profit growth of 108.19%. But I have to remind myself that a cheap price can be a trap if the business quality is poor. This is a chemical trading company, not a brand with pricing power. Its net margin from the latest quarter is roughly 2.9% on ₹1,503 Cr of sales — a thin, competitive business where scale matters more than moat. The ROCE of 14.46% is respectable, but not spectacular. The Piotroski F-Score of 7 out of 9 gives me some comfort that the financial health is improving, but I am troubled by the missing data: no book value, no debt-to-equity ratio, and no promoter holding details. In Graham's world, you need certainty, and gaps in disclosure are red flags. That said, the valuation is compelling. A trailing P/E of 3.80 and a PEG ratio of 0.05 suggest Mr. Market is not awarding any growth premium. If the company can sustain even a fraction of this earnings momentum, the downside appears protected. But I must remember that chemical trading is cyclical and profit growth of 108% can reverse quickly. I would want to see several more quarters of consistent performance before treating this as a true Buffett-style investment. For now, it is a fast grower with a very cheap price but not a proven long-term franchise.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer